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Summary.-The HT29R human colonic adenocarcinoma cell line grows as locally
invasive, mucin-secreting tumours in immunosuppressed mice with a doubling
time of 6 days. These tumours may be disaggregated to give single-cell suspensions
with plating efficiencies of 25-45% in technically simple itn vivo-in vitro cell-survival
assays. The effect of maximum tolerated doses of5-fluorouracil, melphalan and cyclo-
phosphamide on in situ growth is only slight. In vivo-in vitro cell-survival assays
are consistent with these in situ results.
The relative ease of experimental manipulation and the high clonogenic efficiency
of this tumour make it a useful addition to human tumour xenograft models.
IN VIVO-IN VITRO CLONOGENIC ASSAYS
provide an important method of esti-
mating the response of human tumour
xenografts to chemotherapy. Methods of
measuring the clonogenic ability of cells
obtained from disaggregated hetero-
transplanted tumours have been des-
cribed, in which the tumour cells form
colonies in agar either in vitro (Courtenay
& Mills, 1978) or in diffusion chambers
implanted i.p. into mice (Smith et al.,
1976). Such methods, however, are rela-
tively complex to perform and have been
generally reported as giving low plating
efficiencies (PE). This may truly reflect
the small proportions ofpotentially clono-
genic cells in in vivo tumours. Conversely,
these low PEs may be due to technical
problems in the assay, which only allow a
proportion of the clonogenic cells to
divide effectively.
The HT29R human colonic adeno-
carcinoma cell line has already been
investigated for its in situ response to a
number of cytotoxic agents (Warenius
et al., 1980, 1981). This human tumour
cell line might provide a model which
could be experimentaly manipulated with
an ease which was closer to that of
animal-tumour models, but the biological
characteristics and drugresponses ofwhich
were similar to that of heterotransplanted
human tumours primarily established as
xenografts. We have thus attempted to
define the optimal conditions of this
tumour in in vivo-in vitro clonogenic
assays and compare these results to those
of in situ assays.
METHODS
HT29R is a once-recloned variant of the
HT29 cell line (Von Kleist et al., 1975). It was
maintained as a monolayer culture in
McCoy's medium supplemented with 10%
fetal calf serum (FCS) in an atmosphere of
950 air and 5% CO2 at 37TC. Confluent cell
monolayers were removed by incubation
with 1 ml of trypsin (0-125% w/v) in a
solution of EDTA (0-0250o (w/v) in balanced
salt solution (pH 7-4, versene) for 15 min at
37TC. Five ml of McCoy's medium containing
150% FCS were then added, and the cells
pelleted by centrifugation at 600 g for 5 min
on a bench centrifuge. After 2 washes in
McCoy's medium plus 15% FCS, cells were
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resuspended at 107/ml, ready for injection
into mice.
Drugs.-((2-(di(2-chloroethyl)amino- 1-oxa-
3-aza-2-phosphacyclohexane)) Endoxana,
W. B. Pharmaceuticals, CY) was dissolved in
phosphate-buffered saline (PBS). Melphalan
((N,N-p-di-2-chlorethylaminophenylalanine);
Alkeran Injection, Wellcome) was dissolved
in 10% acidified ethanol/propylene glycol-
K2HPO4 buffer. 5-Fluorouracil ((5-fluoropyri-
midine 2,4-(1H,3H)-dione), Roche Products,
FU) was dissolved in PBS. Drug solutions
were prepared immediately before use and
injected i.p. in a volume of0-01 ml/g body wt.
Controls received vehicle alone.
Drugs were tested at maximum tolerated
dose (no more deaths than in control group
and < 15% weight loss) and at lower doses.
Animals.-Male CBA mice were obtained
from O.L.A.C. 1976 (Shaws Farm, Black-
thorne, Bicester). They were immuno-
suppressed by a modification ofthe method of
Kopper & Steel (1975) as previously des-
cribed (Warenius et al., 1980). Mice were
thymectomized at 4 weeks of age and given
9-2 Gy whole-body irradiation from a 60Co
unit 2 weeks later. These animals were recon-
stituted within 12 h by 2x 105 syngeneic
nucleated marrow cells.
In vivo tumours. -Tumours were initiated
by s.c. inoculation of 106 HT29R in vitro cells
24 h after 9-2 Gy total-body irradiation and
marrow reconstitution. Cytotoxic drug treat-
ment was started 21-23 days later, when the
mean tumour volume was 120-150 mm3
(range 80-250 mm3). In order to provide as
much homogeneity as possible in control and
treated groups stratification into subgroups
by volume was carried out and equal pro-
portions of these subgroups were randomized
between the various experimental groups.
Tumours were measured in 2 directions
at right angles by calipers, and their volumes
calculated from the formula 7r/6(d)3. The
validity of this method was tested in an
initial series ofanimals by comparing volumes
determined by caliper measurement with
those determined by volume displacement on
tumours after excision. This showed good
agreement for tumours with volumes between
50 and 800 mm3.
Disaggregation of in vivo tumours.-A
number of disaggregation mixtures were
compared:
A-Trypsin 0.5% w/v, +versene 0.025%
w/v, +DNase 0-2 mg/ml.
B-Pronase 15 mg/ml, +collagenase 10
mg/ml, +versene 0 025% w/v, +DNase
0-2 mg/ml.
C-Collagenase 10 mg/ml, +versene
0.025% w/v, +DNase 0-2 mg/ml.
D-Pronase 15 mg/ml, +versene 0025%
w/v, +DNase 0-2 mg/ml.
All tumours were chopped finely under
sterile condition in just sufficient PBS to keep
the tissue moist. Equal volumes of tumour
brei were then mixed with 5 ml of
the relevant disaggregating solution and
stirred at room temperature for from 30-180
min.
The disaggregated cell suspension was then
filtered through a sterile gauze and a single-
cell suspension obtained by aspiration 2-3
times through a 23-gauge needle.
Clonogenic assays.-Optimal conditions for
colony-forming assays were defined with
regard to culture-medium composition, FCS
concentration and time at which colonies
were assessed. Disaggregated single-cell sus-
pensions were counted and adjusted to
multiples of 100 cells/ml. One ml of each cell
suspension was added to 4 ml of culture
medium supplemented with 15% FCS at 37°C
in tissue-culture grade disposable plastic
Petri dishes (Sterilin 50 mm No. 302V). The
dishes were then incubated for the required
time at 37°C in an atmosphere of95% air and
5% CO2. Adherent colonies were fixed by
95% ethanol for 10 min, stained with Giemsa
and scored under an inverted microscope.
Colonies of 50 cells or more were counted as
colonies. Although relatively large inocula of
cells grew well in either McCoy's 5A medium
or Eagle's medium supplemented with 10%
FCS, both these media gave very poor PE.
The optimal PE conditions were provided by
Ham's F12 medium supplemented with 15%
FCS. For in vitro cells the optimal time for
scoring the number of colonies per dish was
14 days.
For an in vivo-in vitro experiment, the
optimal time was 18 days.
The effect of chemotherapy on in vivo-
in vitro clonogenic assays was assessed by in-
jecting mice i.p. with the relevant drug 24 h
before tumour excision, disaggregation and
assay.
PE was expressed as
no. ofcolonies
no. of viable cells plated
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RESULTS
HT29R grows as a solid, mucin-
secreting poorly differentiated adeno-
carcinoma with a volume-doubling time
of - 6 days.
Disaggregation of HT29 R in vivo tumours
In order to provide viable single-cell
suspensions from solid tumours for in vivo
-in vitro clonogenic assays a number of
different methods of disaggregation were
compared. Fig. 1 shows the cell yield and
viability with time after disaggregation by
3 ofthese methods. Solid symbols show the
total number of cells releasedlg/tumour.
Cell viability was assessed by trypan-blue
exclusion and is shown by the open
symbols. At 120 min, mixtures A and
B produced similar yields, though B
appears initially more effective.
The cell viability as assessed by trypan-
blue exclusion is shown by the open
symbols. This is 85-90% for mixtures A
and B, in which the open symbols can be
seen to follow closely the closed symbols.
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Mixture C, however, composed of colla-
genase, versene and DNase, gives a lower
total yield at all times, and the percentage
ofviable cells can be seen to be very much
lower than for mixtures A and B. Because
of the differences in the numbers of
viable cells released by collagenase,
versene and DNase, as compared to pro-
nase, collagenase, versene and DNase,
the effect of a mixture of pronase alone
with versene and DNase, as well as that
of the other 3 mixtures was tested on the
PE of HT29R in vivo cells. The results of
plating single-cell suspensions after disag-
gregation by these various methods are
shown in Fig. 2. It can be seen that the
tryspin, versene, DNase mixture in panel
A gives the same PE as the pronase,
collagenase, versene, DNase mixture in
panel B at 120 min. Disaggreation mixture
A, however, has more of a plateau at
90-180 min than mixture B. In panel
C it can be seen that the collagenase,
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FiG. I.-The cell yield and viability ofHT29R
in vivo tumours disaggregated by different
methods. A, * Total cells. A Viable cells.
B, * Total cells. O Viable cells. (, * Total
c(ll-.O Viable cells.
4
Fic. 2.- The effect of different methods of
(lisaggregation of in vivo HT29R tumours
on its PE. Letters A-D indicate the res-
pective disaggregating mixtures.
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FIc. 4. The in situ response of HT29R to
cytotoxics. 0 Solvent control. * Drug-
treated. A, 5-fluorouracil 30 mg/kg daily
x 5. B, 5-fluorouracil 146 mg/kg x 1. C,
Cyclophosphamide 180 mg/kg x 1. D,
Melphalan 8 mg/kg x 1. Bars indicate
+ 2 s.e.
versene and DNase mixture gives an
extremely low PE. The highest PE was
achieved by the mixture of pronase alone
alone plus versene and DNase.
In vivo-in vitro clonogenic assays
HT29R tumours were treated in vivo by
i.p. injection of cytotoxic drugs 24 h be-
fore tumour excision. Disaggregation was
carried out using the mixture D of
pronase, versene and DNase which had
given PEs of 45% for untreated
tumours. The two alkylating agents,
melphalan and CY, shown in Fig, 3A &
B, have large shoulders on their survival
curves. The curves do not begin to descend
steeply until doses exceed the maximum
tolerated dose of 180 mg/kg for CY, and
8 mg/kg for melphalan. It can be seen that
even the LD50/30 dose for CY (270
mg/kg) only caused a reduction of 50% in
PE. The cell-survival curves for CY and
melphalan show increasing cell kill with
increasing dose.
The cell-survival curve for 5-fluoro-
uracil FU (C) is different, having an
initial drop but subsequently flattening
out. As with CY and melphalan, doses of
FU of the order of the LD50/30 (220
mg/kg) have only a small effect on PE.
Effect of chemotherapy on in vivo tumours
The effects of the drugs CY, FU and
melphalan on the in situ growth ofHT29R
are shown in Fig. 4. The maximum tole-
rated dose of FU as a single i.p. injection
or 5 daily injections was 146 mg/kg. Both
the single FU injection and the 5 daily
injections produced a significant inhibition
of tumour growth at 12 days. This inhibi-
tion was not marked, however, and by
Day 18 the difference between treated and
control groups was already much smaller.
Tumour measurements were discon-
tinued in most experiments after Day 18
because of the high percentage of
ulceration. The drugs CY, (C) and mel-
phalan (D) produced less inhibition of
growth of the HT29R tumour than did
FU. For melphalan, it was not possible,
with the size of the experiment used, to
demonstrate any statistically significant
inhibition ofgrowth.
DISCUSSION
A disadvantage ofthe small response of
HT29R to maximum tolerated doses of
cytotoxic drugs in vivo is that it is
impossible to perform in situ growth delay
experiments without using very large
numbers of animals in each treatment
group. Also, when drugs only give slight
inhibition of in vivo tumour growth, it is
not practicable to produce dose-response
curves.
These facts, coupled with the other
problems of in situ growth-delay assays in
heterotransplanted tumours, such as
residual host immunity, make the use of
in vivo-in vitro cell-survival assays
particularly appealing.
In vivo-in vitro clonogenic assays with
high PE can be performed on HT29R
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using a simple technique of plating single-
cell suspensions into tissue-culture-grade
Petri dishes, where they form adherent
colonies. These colonies can be scored
after 18 days' incubation. HT29R will
also produce colonies in soft agar, and in
diffusion chambers implanted i.p. into
immunosuppressed mice (unpublished).
WVe are at present comparing these techni-
ques with the assay using adherent cells. In
terms ofPE the duration of incubation re-
quired before colonies can be scored, and
ease of manipulation, the HT29R clono-
genic system compares favourably with
previously reported clonogenic assays of
heterotransplanted tumours (Smith et al.,
1976; Courtenay & Mills, 1978). However,
the latter were performed on xenografts
derived as primary heterotransplants
from human tumours, whereas HT29R
has been established as an in vitro cell line
for > 100 passages.
A great degree of selection is likely to
occur when we attempt to perpetuate
individual human tumours as replicable
model systems under experimental con-
ditions. Thus, how closely the behaviour
of any human tumour model system re-
flects that of the primary from which it
is derived must be uncertain. Also, as has
been pointed out by Steel & Peckham
(1980), individual differences in the res-
ponse of xenografts to chemotherapy
make it unlikely that anv one xenograft
tumour can be a representative model.
Although HT29R is an established in
vitro cell line, it is capable of growth as
p)oorly differentiated mucin-secreting
adenocarcinomas which invade locally.
The mean volume-doubling time of these
tumours (6 days) is comparable to that of
some established colonic adenocarcinoma
heterotransplants such as HX13 and
HX18 (Kopper & Steel, 1975).
In this paper we have shown that
HT29R responds poorly to FU (one of the
most useful agents clinically against
colon cancer) and also to the 2 alky-
lating agents melphalan and CY. The
in 8itu response to methyl CCNU (not
shown) was similar to that for melphalan.
The in vivo-in vitro cell-survival dose-
response curves with the 2 bifunctional
alkylating agents CY and melphalan are
characterized by large shoulders exten-
ding to LD50/30 doses for each of the
drugs in question.
Because only small differences can be
shown in in vivo-in vitro cell survival wlth
doses of drug which are less than the
LD50/30, and because there is only slight
growth inhibition in in situ growth assays
with doses below the MTD, it is not
possible to correlate the 2 assays
nuimerically. However, the in vivo-in
vitro cell-survival assay is consistent, with
the in situ growth-delay assays, in that
both show very little response to the
MTD of the relevant cytotoxic agents.
The cell-survival curve for FU contrasts
with that for the alkylating agents, in that
it flattens out with increasing doses. This
appearance is consistent with FU behaving
as a phase-specific agent under these
conditions.
HT29R would thus appear to provide a
useful human tumour xenograft model
with a poor response to chemotherapy and
a technically simple in vivo-in vitro
clonogenic assay system with high
plating efficiency.
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